 | Up a level |
2020
Haentschel, Maik, Boeckeler, Michael, Bonzheim, Irina, Schimmele, Florian, Spengler, Werner, Stanzel, Franz, Petermann, Christoph, Darwiche, Kaid, Hagmeyer, Lars, Buettner, Reinhard, Tiemann, Markus, Schildhaus, Hans-Ulrich, Muche, Rainer, Boesmueller, Hans, Everinghoff, Felix, Mueller, Robert, Atique, Bijoy, Lewis, Richard A., Zender, Lars, Fend, Falko and Hetzel, Juergen (2020). Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. Diagnostics, 10 (7). BASEL: MDPI. ISSN 2075-4418
2019
Michels, Sebastian, Heydt, Carina, van Veggel, Bianca, Deschler-Baier, Barbara, Pardo, Nuria, Monkhorst, Kim, Ruesseler, Vanessa, Stratmann, Jan, Griesinger, Frank, Steinhauser, Susanne, Kostenko, Anna, Diebold, Joachim, Fassunke, Jana, Fischer, Rieke, Engel-Riedel, Walburga, Gautschi, Oliver, Geissinger, Eva, Haneder, Stefan, Ihle, Michaela A., Kopp, Hans-Georg, de Langen, Adrianus J., Martinez-Marti, Alex, Nogova, Lucia, Persigehl, Thorsten, Plenker, Dennis, Puesken, Michael, Rodermann, Ernst, Rosenwald, Andreas, Scheel, Andreas H., Scheffler, Matthias, Spengler, Werner, Seggewiss-Bernhardt, Ruth, Braegelmann, Johannes, Sebastian, Martin, Vrugt, Bart, Hellmich, Martin, Sos, Martin L., Heukamp, Lukas C., Felip, Enriqueta, Merkelbach-Bruse, Sabine, Smit, Egbert F., Buettner, Reinhard and Wolf, Juergen (2019). Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precis. Oncol., 3. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 2473-4284
2018
Stratmann, Jan A., Michels, Sebastian, Hornetz, Sofia, Christoph, Daniel C., Sackmann, Sandra, Spengler, Werner, Bischoff, Helge, Schaefer, Monica, Alt, Juergen, Mueller, Annette, Laack, Eckart, Kimmich, Martin, Griesinger, Frank and Sebastian, Martin (2018). Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J. Cancer Res. Clin. Oncol., 144 (12). S. 2457 - 2464. NEW YORK: SPRINGER. ISSN 1432-1335